DWC202510

DWC202510 is a code name used by Daewoong Pharmaceutical to identify the reference drug, **Lynparza** (olaparib), in its clinical bioequivalence programs. Olaparib is a first-in-class, orally administered small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. It is primarily used to treat cancers associated with deficiencies in homologous recombination repair (HRR), such as those harboring BRCA1 or BRCA2 mutations. The drug's mechanism of action involves inhibiting PARP enzymes and trapping them at sites of single-strand DNA breaks, which prevents repair and leads to the formation of double-strand breaks during DNA replication. In cells with defective HRR pathways, these breaks cannot be accurately repaired, resulting in genomic instability and cell death—a therapeutic strategy known as synthetic lethality. In the context of Daewoong's development pipeline, DWC202510 serves as the comparator for their generic olaparib candidate, DWZ2501, specifically in studies involving patients with advanced BRCA-mutated high-grade ovarian cancer.

Brand names

Lynparza

Other names

olaparibAZD2281AZD-2281AZD 2281KU-0059436KU0059436KU 0059436